查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417560

週边神经病变市场报告：2030 年趋势、预测与竞争分析

Peripheral Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

週边神经病变的趋势和预测

预计 2024 年至 2030 年，全球週边神经病变市场将以 7.0% 的复合年增长率成长。该市场的主要驱动力是老年人和肥胖人口的快速增长以及糖尿病的增加。全球週边神经病变市场的未来充满希望，医院/诊所和门诊中心市场充满机会。

週边神经病变市场洞察

Lucintel 预测，在预测期内，药物治疗将继续占据较大份额，因为它更有效且更容易使用。

在这个市场中，医院和诊所将继续成为较大的细分市场，因为这些设施提供多种治疗方法以及专家的存在。

由于糖尿病盛行率高且医疗基础设施发达，北美在预测期内仍是最大的地区。

常问问题

Q1.市场成长预测如何？

A1. 预计 2024 年至 2030 年，全球週边神经病变市场将以 7.0% 的复合年增长率成长。

Q2.影响市场成长的主要驱动因素有哪些？

A2. 这个市场的主要驱动因素是老年人和肥胖人口的快速增加以及糖尿病的增加。

Q3.市场的主要细分市场有哪些？

A3. 週边神经病变市场的未来性充满希望，医院/诊所和门诊中心市场充满机会。

Q4.市场上主要企业有哪些？

A4.週边神经病变的主要企业如下。

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计药物治疗在预测期内仍将占据较大份额，因为它更有效且更易于使用。

Q6. 未来五年预计哪个地区将成为最大的市场？

A6. 由于糖尿病盛行率高且医疗基础设施发达，北美在预测期内仍将是最大的地区。

Q7. 可以客製化报告吗？

A7. 是的，Lucintel 提供 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球週边神经病变市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球週边神经病变市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球週边神经病变市场
    • 糖尿病週边神经病变
    • 化疗引起的周边神经病变
    • 特发性週边神经病变
    • HIV/爱滋病相关的周边神经病变
  • 按治疗分類的全球週边神经病变市场
    • 药物治疗
    • 非药物治疗
    • 其他的
  • 按最终用途分類的全球週边神经病变市场
    • 医院和诊所
    • 门诊中心
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球週边神经病变市场（按地区）
  • 北美週边神经病变市场
  • 欧洲週边神经病变市场
  • 亚太週边神经病变市场
  • 其他地区週边神经病变市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球週边神经病变市场成长机会
    • 全球週边神经病变市场的治疗成长机会
    • 全球週边神经病变市场成长机会（依最终用途）
    • 全球週边神经病变市场按地区成长机会
  • 全球週边神经病变市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球週边神经病变市场的产能扩张
    • 全球週边神经病变市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer
简介目录

Peripheral Neuropathy Trends and Forecast

The future of the global peripheral neuropathy market looks promising with opportunities in the hospital and clinic and ambulatory center markets. The global peripheral neuropathy market is expected to grow with a CAGR of 7.0% from 2024 to 2030. The major drivers for this market are surge in geriatric and obese population and increasing occurence of diabetes.

A more than 150-page report is developed to help in your business decisions.

Peripheral Neuropathy by Segment

The study includes a forecast for the global peripheral neuropathy by type, treatment, end use, and region.

Peripheral Neuropathy Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Diabetic Peripheral Neuropathy
  • Chemotherapy-Induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy

Peripheral Neuropathy Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Pharmacological Therapies
  • Non-Pharmacological Therapies
  • Others

Peripheral Neuropathy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Ambulatory Centers
  • Others

Peripheral Neuropathy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Peripheral Neuropathy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peripheral neuropathy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peripheral neuropathy companies profiled in this report include-

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer

Peripheral Neuropathy Market Insights

Lucintel forecasts that pharmacological therapy will remain the larger segment over the forecast period as it is more effective and easy to use.

Within this market, hospital and clinic will remain the larger segment due to availability of different treatment methods along with presence of expertise in these facilities.

North America will remain the largest region over the forecast period due to high prevalence of diabetes patients and presence of healthcare infrastructure in the region.

Features of the Global Peripheral Neuropathy Market

Market Size Estimates: Peripheral neuropathy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Peripheral neuropathy market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Peripheral neuropathy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatment, end uses, and regions for the peripheral neuropathy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peripheral neuropathy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for peripheral neuropathy market?

Answer: The global peripheral neuropathy market is expected to grow with a CAGR of 7.0% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the peripheral neuropathy market?

Answer: The major drivers for this market are surge in geriatric and obese population and increasing occurence of diabetes.

Q3. What are the major segments for peripheral neuropathy market?

Answer: The future of the peripheral neuropathy market looks promising with opportunities in the hospital and clinic and ambulatory center markets.

Q4. Who are the key peripheral neuropathy market companies?

Answer: Some of the key peripheral neuropathy companies are as follows.

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer

Q5. Which peripheral neuropathy market segment will be the largest in future?

Answer: Lucintel forecasts that pharmacological therapy will remain the larger segment over the forecast period as it is more effective and easy to use.

Q6. In peripheral neuropathy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of diabetes patients and presence of healthcare infrastructure in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the peripheral neuropathy market by type (diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, idiopathic peripheral neuropathy, and HIV/AIDS associated peripheral neuropathy), treatment (pharmacological therapies, non-pharmacological therapies, and others), end use (hospitals and clinics, ambulatory centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peripheral Neuropathy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Peripheral Neuropathy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Peripheral Neuropathy Market by Type
    • 3.3.1: Diabetic Peripheral Neuropathy
    • 3.3.2: Chemotherapy-induced Peripheral Neuropathy
    • 3.3.3: Idiopathic Peripheral Neuropathy
    • 3.3.4: HIV/AIDS Associated Peripheral Neuropathy
  • 3.4: Global Peripheral Neuropathy Market by Treatment
    • 3.4.1: Pharmacological Therapies
    • 3.4.2: Non-Pharmacological Therapies
    • 3.4.3: Others
  • 3.5: Global Peripheral Neuropathy Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Ambulatory Centers
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Peripheral Neuropathy Market by Region
  • 4.2: North American Peripheral Neuropathy Market
    • 4.2.1: North American Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.2.2: North American Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.3: European Peripheral Neuropathy Market
    • 4.3.1: European Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.3.2: European Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.4: APAC Peripheral Neuropathy Market
    • 4.4.1: APAC Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.4.2: APAC Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.5: ROW Peripheral Neuropathy Market
    • 4.5.1: ROW Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.5.2: ROW Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Peripheral Neuropathy Market by Type
    • 6.1.2: Growth Opportunities for the Global Peripheral Neuropathy Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Peripheral Neuropathy Market by End Use
    • 6.1.4: Growth Opportunities for the Global Peripheral Neuropathy Market by Region
  • 6.2: Emerging Trends in the Global Peripheral Neuropathy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Peripheral Neuropathy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peripheral Neuropathy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abbott
  • 7.2: Bristol Myers Squibb
  • 7.3: Novartis
  • 7.4: Eli Lilly
  • 7.5: Pfizer